{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:30:51Z","timestamp":1777401051673,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"MSD UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.lungcan.2022.05.018","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:11:48Z","timestamp":1653736308000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9\u201315 PROMISE-meso phase III trial"],"prefix":"10.1016","volume":"169","author":[{"given":"Giuseppe Luigi","family":"Banna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Zygoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi","family":"Tsourti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Dieter","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"L\u00f3pez-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Roschitzki-Voser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urania","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf A.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2022.05.018_b0005","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.018_b0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.018_b0015","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2022.05.018_b0020","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2022.05.018_b0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2022.05.018_b0030","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2021.08.2146","article-title":"LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743","volume":"32","author":"Peters","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.018_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100078","article-title":"The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 >\/= 50% advanced non-small-cell lung cancer","volume":"6","author":"Banna","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.018_b0040","doi-asserted-by":"crossref","first-page":"100118","DOI":"10.1016\/j.esmoop.2021.100118","article-title":"Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort","volume":"6","author":"Fornarini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2022.05.018_b0045","doi-asserted-by":"crossref","unstructured":"S.E. Rebuzzi A. Signori G.L. Banna M. Maruzzo U. De Giorgi P. Pedrazzoli A. Sbrana P.A. Zucali C. Masini E. Naglieri G. Procopio S. Merler L. Tomasello L. Fratino C. Baldessari R. Ricotta S. Panni V. Mollica M. Sorar\u00f9 M. Santoni A. Cortellini V. Prati H.J. Soto Parra M. Stellato F. Atzori S. Pignata C. Messina M. Messina F. Morelli G. Prati F. Nol\u00e8 F. Vignani A. Cavo G. Roviello F. Pierantoni C. Casadei M. Bersanelli S. Chiellino F. Paolieri M. Perrino M. Brunelli R. Iacovelli C. Porta S. Buti G. Fornarini Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study), Therapeutic Advances Medical Oncology 13 2021 17588359211019642.","DOI":"10.1177\/17588359211019642"},{"key":"10.1016\/j.lungcan.2022.05.018_b0050","doi-asserted-by":"crossref","unstructured":"S. Popat A. Curioni-Fontecedro V. Polydoropoulou R. Shah M. O\u2019Brien A. Pope P. Fisher J. Spicer A. Roy D. Gilligan O. Gautschi E. Nadal W.-D. Janthur R. L\u00f3pez Castro R. Garc\u00eda Campelo H. Roschitzki-Voser B. Ruepp S. Rusakiewicz S. Peters R.A. Stahel A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial Annals of Oncology 30 2019 v931 v931.","DOI":"10.1093\/annonc\/mdz394.091"},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.018_b0055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2005-07-3046","article-title":"The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?","volume":"107","author":"Beutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2022.05.018_b0060","series-title":"Hematology (Seventh Edition)","first-page":"e1","article-title":"Chapter 162 - Resources for the Hematologist: Interpretive Comments and Selected Reference Values for Neonatal, Pediatric, and Adult Populations","author":"Marcogliese","year":"2018"},{"key":"10.1016\/j.lungcan.2022.05.018_b0065","unstructured":"L. Dean Chapter 1, Blood and the cells it contains L. Dean Blood Groups and Red Cell Antigens [Internet] (US)2005. National Center for Biotechnology Information Bethesda (MD)."},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.018_b0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.smj.0000209275.75045.d4","article-title":"Thrombocytopenia in adults: A practical approach to evaluation and management","volume":"99","author":"Sekhon","year":"2006","journal-title":"South. Med. J."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.018_b0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.018_b0080","doi-asserted-by":"crossref","unstructured":"J. Rossaint, A. Margraf, A. Zarbock, Role of Platelets in Leukocyte Recruitment and Resolution of Inflammation, Front Immunol 9 (2018) 2712-2712.","DOI":"10.3389\/fimmu.2018.02712"},{"issue":"09","key":"10.1016\/j.lungcan.2022.05.018_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1160\/TH14-12-1067","article-title":"The role of platelets in inflammation","volume":"114","author":"Thomas","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.018_b0090","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.018_b0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thor. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.018_b0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.018_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2022.02.030","article-title":"Systemic therapy for pre-treated malignant mesothelioma: a systematic review, meta-analysis and network meta-analysis of randomised controlled trials","volume":"166","author":"Banna","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.018_b0110","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1038\/s41598-021-90397-y","article-title":"Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study","volume":"11","author":"Kauffmann-Guerrero","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.018_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100118","article-title":"Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort","volume":"6","author":"Fornarini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2022.05.018_b0120","doi-asserted-by":"crossref","unstructured":"S.E. Rebuzzi A. Signori G.L. Banna M. Maruzzo U. De Giorgi P. Pedrazzoli A. Sbrana P.A. Zucali C. Masini E. Naglieri G. Procopio S. Merler L. Tomasello L. Fratino C. Baldessari R. Ricotta S. Panni V. Mollica M. Soraru M. Santoni A. Cortellini V. Prati H.J. Soto Parra M. Stellato F. Atzori S. Pignata C. Messina M. Messina F. Morelli G. Prati F. Nole F. Vignani A. Cavo G. Roviello F. Pierantoni C. Casadei M. Bersanelli S. Chiellino F. Paolieri M. Perrino M. Brunelli R. Iacovelli C. Porta S. Buti G. Fornarini Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study), Ther Adv Med Oncol 13 2021 17588359211019642.","DOI":"10.1177\/17588359211019642"},{"issue":"16","key":"10.1016\/j.lungcan.2022.05.018_b0125","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"Blayney","year":"2012","journal-title":"Eur. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222004639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222004639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:00:53Z","timestamp":1759237253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222004639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"alternative-id":["S0169500222004639"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9\u201315 PROMISE-meso phase III trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}